Eli Lilly Canada (LLY) Announces Health Canada has approved TALTZ for Treatment of Active Ankylosing Spondylitis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to Eli Lilly Canada (LLY) Announces Health Canada has approved TALTZ for Treatment of Active Ankylosing Spondylitis

Health Canada has approved TALTZ® (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)

February 11, 2020 6:45 AM EST

TORONTO, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Eli Lilly Canada announced today that Health Canada approved TALTZ® (ixekizumab) on February 4, 2020, for the treatment of adult patients with active ankylosing spondylitis (AS), which is also known as radiographic axial spondyloarthritis (r-axSpA), who have responded inadequately to, or are intolerant to, conventional therapy. This is the third indication for TALTZ, which was first approved by Health Canada for moderate- to severe plaque psoriasis and psoriatic arthritis in 2016 and 2018, respectively.

People living with ankylosing spondylitis deal with a considerable amount of pain and anxiety. If left untreated, it can severely affect... More